Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

BIIB

Biogen Inc

Feb 06 • 04:00PM ET

201.18

+15.82 8.53 %

Healthcare • Drug Manufacturers - General • USA • NASD

Today, 12:32 PMBiogen shares rise after a Q4 earnings and revenue beat as FY2025 EPS of $15.28 and revenue of $9.9B top prior guidance, and the company raises 2026 adjusted EPS outlook to $15.25–$16.25 above expectations despite revenue headwinds, with its pipeline inflecting.

Peers: VRTX GILD REGN AMGN MRK PFE BMY LLY JNJ NBIX

| Held by: VTI VOO VO IVV SPY VTV XLV IBB RSP VOE

Index	S&P 500	P/E	22.85	EPS (ttm)	8.81	Insider Own	0.18%	Shs Outstand	146.70M	Perf Week	11.84%
Market Cap	29.51B	Forward P/E	12.82	EPS next Y	15.69	Insider Trans	-0.48%	Shs Float	146.44M	Perf Month	7.63%
Enterprise Value	32.28B	PEG	4.73	EPS next Q	3.38	Inst Own	92.20%	Short Float	3.19%	Perf Quarter	31.12%
Income	1.29B	P/S	3.06	EPS this Y	0.30%	Inst Trans	1.61%	Short Ratio	2.40	Perf Half Y	57.48%
Sales	9.63B	P/B	1.62	EPS next Y	2.38%	ROA	4.50%	Short Interest	4.68M	Perf YTD	14.31%
Book/sh	124.11	P/C	7.73	EPS next 5Y	2.71%	ROE	7.39%	52W High	190.20 5.77%	Perf Year	38.24%
Cash/sh	26.01	P/FCF	12.81	EPS past 3/5Y	-25.04% -18.74%	ROIC	5.21%	52W Low	110.04 82.83%	Perf 3Y	-30.84%
Dividend Est.	-	EV/EBITDA	9.95	Sales past 3/5Y	1.59% -4.35%	Gross Margin	75.04%	Volatility	4.40% 3.38%	Perf 5Y	-28.81%
Dividend TTM	-	EV/Sales	3.35	EPS Y/Y TTM	-21.29%	Oper. Margin	26.00%	ATR (14)	6.00	Perf 10Y	-20.07%
Dividend Ex-Date	-	Quick Ratio	2.03	Sales Y/Y TTM	3.94%	Profit Margin	13.42%	RSI (14)	74.19	Recom	2.36
Dividend Gr. 3/5Y	- -	Current Ratio	2.68	EPS Q/Q	-118.25%	SMA20	13.56%	Beta	0.15	Target Price	197.50
Payout	0.00%	Debt/Eq	0.36	Sales Q/Q	-2.49%	SMA50	13.33%	Rel Volume	1.75	Prev Close	185.36
Employees	7605	LT Debt/Eq	0.36	Earnings	Feb 06 BMO	SMA200	36.49%	Avg Volume	1.95M	Price	201.18
IPO	Sep 17, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	22.45% 3.48%	Trades		Volume	3,404,217	Change	8.53%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-26	Resumed	UBS	Neutral	$185
Dec-10-25	Downgrade	HSBC Securities	Hold → Reduce	$143
Nov-06-25	Upgrade	Stifel	Hold → Buy	$202
Sep-25-25	Initiated	Jefferies	Buy	$190
Jul-21-25	Resumed	Truist	Hold	$142
Apr-28-25	Downgrade	HSBC Securities	Buy → Hold	$118
Apr-04-25	Downgrade	Argus	Buy → Hold
Feb-11-25	Initiated	Bernstein	Mkt Perform	$160
Jan-02-25	Downgrade	Piper Sandler	Overweight → Neutral	$315 → $138
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$230 → $164
Dec-16-24	Downgrade	Stifel	Buy → Hold	$175
Dec-10-24	Resumed	BofA Securities	Neutral	$178
Dec-09-24	Downgrade	Jefferies	Buy → Hold	$250 → $180
Nov-18-24	Downgrade	Needham	Buy → Hold
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-14-24	Initiated	Citigroup	Neutral	$190
Oct-31-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$285 → $204
Oct-10-24	Resumed	Raymond James	Mkt Perform
Feb-14-24	Reiterated	Needham	Buy	$305 → $300
Feb-14-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$315 → $240

Show Previous Ratings

Today 07:43PM	Analyst Report: Biogen Inc. (Morningstar Research) +8.53%
06:09AM	How One Drug Heavy-Lifted Biogen's Fourth-Quarter Beat (Investor's Business Daily)
04:02PM	Biogen Inc (BIIB) Q4 2025 Earnings Call Highlights: Strong Growth in Key Products Amidst ... (GuruFocus.com)
03:48PM	Biogen stock pops, Robinhood gets lift as bitcoin ticks up (Yahoo Finance Video)
07:35AM	Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio. (Barrons.com)
11:30AM	Loading…
11:30AM	BIIB Beats on Q4 Earnings & Sales, Stock Gains on Upbeat '26 EPS View (Zacks)
11:15AM	Biogen Forecasts 2026 Profit Above Estimates as Shares Climb 30% (GuruFocus.com)
11:12AM	Pre-Markets Open in Green to Close the Week (Zacks)
10:33AM	Biogen Hits 52-Week High, Alzheimer's Drug Sales Jump (Benzinga)
10:29AM	Pre-Markets Rebounding Ahead of Super Bowl Sunday (Zacks)
10:10AM	Biogen Q4 Earnings Call Highlights (MarketBeat)
09:42AM	Stock Market Today: Dow Rallies, Bitcoin Bounces; Amazon Dives On Earnings Results (Live Coverage) (Investor's Business Daily)
09:30AM	Biogen (BIIB) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:59AM	Biogen Revenue Down as Multiple Sclerosis Sales Slide (The Wall Street Journal)
08:59AM	Biogen 4Q Revenue Down as Multiple Sclerosis Sales Slide (The Wall Street Journal)
07:17AM	Loading…
07:17AM	Biogen's (NASDAQ:BIIB) Q4 CY2025: Strong Sales (StockStory)
07:15AM	Biogen Inc. (BIIB) Q4 Earnings and Revenues Top Estimates (Zacks)
07:03AM	Biogen shares rise as Q4 earnings beat expectations, 2026 profit outlook strong (Investing.com)
05:39AM	Consumer Sentiment, Biogen Earnings: What to Watch Friday (The Wall Street Journal)
05:35AM	Stocks to Watch Friday: Amazon, Roblox, Stellantis, Strategy (The Wall Street Journal)
Feb-05-26 07:00PM	Under Armour earnings, Fed, Liftoff Mobile IPO: What to Watch (Yahoo Finance Video)
04:27AM	Amazon and Biogen Earnings: Still to Watch This Week (The Wall Street Journal)
Feb-04-26 10:02PM	Biogen (BIIB) Reports Q4: Everything You Need To Know Ahead Of Earnings (StockStory)
04:01PM	Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (Business Wire)
07:30AM	Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy (GlobeNewswire)
04:36AM	Big Tech and Pharma Earnings: What to Watch This Week (The Wall Street Journal)
Feb-03-26 02:57PM	These Are The Worst 25 Stocks to Own in February (Schaeffer's Research)
10:00AM	Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
07:56AM	New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings (Zacks)
Feb-01-26 07:47AM	January jobs data, Alphabet and Amazon earnings, more Warsh fallout: What to watch this week (Yahoo Finance)
10:00AM	Loading…
Jan-30-26 10:00AM	Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jan-29-26 04:09PM	Phillip Allen Sharp Improved Human Health With Breakthroughs (Investor's Business Daily)
08:53AM	Biogen's Autoimmune Disease Candidate Gets FDA's Breakthrough Status (Zacks)
06:06AM	FDA grants breakthrough status to Biogen's litifilimab for CLE (Pharmaceutical Business Review)
Jan-28-26 12:47PM	Pharma Stocks Are Close to 'Breaking Out.' Earnings Could Set Them Free. (Barrons.com)
07:30AM	Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options (GlobeNewswire)
Jan-25-26 06:30PM	FDA Accepts LEQEMBI IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review (PR Newswire)
06:30PM	FDA Accepts LEQEMBI IQLIK (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review (GlobeNewswire)
Jan-22-26 09:00AM	Investors load Corxel with $287M for a differentiated obesity pill (BioPharma Dive)
Jan-20-26 08:28AM	3 Biotech Stocks That Look Like "Sure-Fire" Winners in 2026 (MarketBeat)
Jan-14-26 08:46AM	What to Expect From Biogen's Next Quarterly Earnings Report (Barchart) -5.04%
Jan-13-26 11:45AM	JPM26: Biotechs M&A lift, the new Biogen and Mercks $70B target (BioPharma Dive)
09:11AM	Biogen CEO Chris Viehbacher on 2026 drug pipeline outlook, rare disease strategy (CNBC TV)
03:02AM	Biogen CEO Says New Drugs Offset MS Decline, Eyes 2026 Transformational Era at JPMorgan Conference (MarketBeat)
Jan-12-26 11:05AM	Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA (nusinersen) for Spinal Muscular Atrophy (GlobeNewswire)
Jan-11-26 11:05PM	3 Reasons to Sell BIIB and 1 Stock to Buy Instead (StockStory)
02:00PM	Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome (Business Wire)
Jan-10-26 02:57PM	Here's What Analysts Think About Biogen Inc. (BIIB) (Insider Monkey)
Jan-07-26 01:01PM	Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up (Zacks)
Jan-05-26 08:00PM	Biologics License Application for Subcutaneous Formulation of "LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China (GlobeNewswire)
01:52PM	Biotech and Pharma Stocks Tumble as Investors Race into Energy (Barrons.com)
07:02AM	Samsung Bioepis initiates Byooviz commercialisation in Europe (Pharmaceutical Business Review)
Jan-02-26 07:44AM	Here's How AbbVie's Neuroscience Portfolio Is Aiding Top-line Growth (Zacks)
Dec-29-25 10:03AM	UnitedHealth Works Toward Recovery and 4 More Healthcare Themes to Watch in 2026 (Barrons.com)
Dec-28-25 03:00AM	5 Healthcare Themes for Investors to Watch in 2026 (Barrons.com)
Dec-22-25 11:20AM	The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS (GlobeNewswire)
Dec-21-25 10:31PM	Therapeutics Stocks Q3 In Review: Biogen (NASDAQ:BIIB) Vs Peers (StockStory)
Dec-19-25 11:50AM	Biogen (BIIB) Stock Trades Up, Here Is Why (StockStory)
Dec-17-25 05:13PM	HSBC Downgrades Biogen Inc. (BIIB) to Reduce Despite Pipeline Progress (Insider Monkey)
01:40PM	MicroStrategy Gets to Stay in the Nasdaq-100. Does It Deserve to Stay in Your Portfolio Too? (Barchart)
Dec-16-25 01:15PM	Biotech Leader Stoke Therapeutics Offers Multiple Entries As Revenue Surges 117% (Investor's Business Daily)
Dec-15-25 12:15PM	MicroStrategy retains place in key index despite delisting threats (TheStreet)
10:05AM	Lululemon Set to Exit Nasdaq 100 as Index Adds New Members (GuruFocus.com)
09:11AM	Western Digital stock rises after inclusion in Nasdaq-100 Index (Investing.com)
07:03AM	200% Surge? These 6 Stocks Just Crashed the Nasdaq 100 Party (GuruFocus.com)
Dec-13-25 11:04AM	Walmart was too late for a Nasdaq-100 spot - but these 6 stocks made the cut (MarketWatch)
Dec-12-25 08:21PM	Bitcoin hoarding company Strategy remains in Nasdaq 100 (Reuters)
04:53AM	Analysts flag risks for Strategy at Nasdaq 100 index reshuffle (Reuters)
Dec-10-25 11:31PM	3 Healthcare Stocks We Think Twice About (StockStory)
12:40PM	ASH 2025: AbbVie and Genmabs Epkinly sets new standard in second-line FL (Clinical Trials Arena)
11:13AM	Fed Cuts Rates for Third Time This Year, Signals One More in 2026 (Barchart)
09:40AM	Amazon initiated, GE Vernova upgraded: Wall Street's top analyst calls (The Fly)
09:09AM	Here Are Wednesdays Top Wall Street Analyst Research Calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More (24/7 Wall St.)
08:36AM	HSBC highlights one pharma stock to buy and one to sell for 2026 (Investing.com)
04:47AM	Health Canada approves Biogen's Zurzuvae for PPD treatment (Pharmaceutical Business Review)
Dec-08-25 06:30PM	"LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List (GlobeNewswire)
01:53PM	Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business? (Zacks)
03:37AM	Is Biogen Stock Outperforming the Dow? (Barchart)
Dec-05-25 11:30AM	Revolution Medicines (RVMD) Up 27.9% Since Last Earnings Report: Can It Continue? (Zacks)
09:56AM	Denali Enters Into a $275M Funding Deal With Royalty Pharma (Zacks)
09:00AM	Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting (GlobeNewswire)
Dec-03-25 06:10PM	Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 (GlobeNewswire)
11:30AM	Why Is Myriad (MYGN) Up 8.7% Since Last Earnings Report? (Zacks)
07:26AM	Tech Is Getting Left Behind in the S&P 500s Latest Rebound (Bloomberg)
Dec-02-25 04:40PM	New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI (lecanemab-irmb) on Neurotoxic Aß Protofibrils in CSF (PR Newswire)
Dec-01-25 07:30AM	Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting (Business Wire)
07:30AM	Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting (GlobeNewswire)
Nov-27-25 07:30PM	Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI" for the Treatment of Early Alzheimer's Disease in Japan (GlobeNewswire)
Nov-26-25 05:30AM	Hedge Funds Pile Into Health Stocks Leading Market in Rotation (Bloomberg)
Nov-25-25 12:28PM	FDA Decision Opens Bigger Market for Novartis's Blockbuster Gene Therapy (Barrons.com)
10:43AM	Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline (Zacks)
07:30AM	Eisai Completes Rolling Submission to US FDA for LEQEMBI IQLIK (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status (GlobeNewswire)
Nov-24-25 04:33PM	Novo Dives After Weight-Loss Pill Fails In Alzheimer's Disease; Biogen Jumps (Investor's Business Daily)
11:46AM	Novo's $5 Billion Alzheimer's Dream Just Died--And Investors Are Cratering the Stock (GuruFocus.com)
11:35AM	Stock Market Today: Dow, Nasdaq Up As This Stock Tests Entry; Health Plays Pop (Live Coverage) (Investor's Business Daily)
11:34AM	Novo Nordisk Stock Falls. Why Its Alzheimer's Trial News Is Hitting Shares. (Barrons.com)
10:40AM	Novo Nordisks Alzheimers Trials Were a Long Shot. Their Failure Is Still Hitting the Stock. (Barrons.com)
10:26AM	Stock Market Today: Dow Jones Rises, Techs Jump; Google Pops On Salesforce Praise, Novo Nordisk Dives (Investor's Business Daily)
09:22AM	Biogen to gain from Novo Nordisk Alzheimers failure, says Jefferies (Investing.com)
07:30AM	Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions (GlobeNewswire)

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Singhal Priya	Head of Development	Jan 30 '26	Option Exercise	0.00	1,829	0	7,601	Feb 03 05:17 PM
Singhal Priya	Head of Development	Feb 02 '26	Sale	179.30	748	134,116	6,271	Feb 03 05:17 PM
Singhal Priya	Officer	Feb 02 '26	Proposed Sale	179.30	748	134,116		Feb 02 11:10 AM
Viehbacher Christopher	President and CEO	Dec 01 '25	Option Exercise	0.00	7,040	0	19,847	Dec 03 04:42 PM
Grogan Jane	Head of Research	Oct 31 '25	Option Exercise	0.00	695	0	2,128	Nov 04 04:12 PM
Godbout Sean	Chief Accounting Officer	Oct 02 '25	Option Exercise	0.00	26	0	503	Oct 06 01:00 PM
Singhal Priya	Head of Development	Aug 29 '25	Option Exercise	0.00	1,669	0	7,096	Sep 02 05:56 PM
Singhal Priya	Head of Development	Sep 02 '25	Sale	133.55	517	69,045	5,772	Sep 02 05:56 PM
Singhal Priya	Officer	Sep 02 '25	Proposed Sale	133.55	517	69,045		Sep 02 12:54 PM
Izzar Rachid	Head of Global Product Strat.	Jul 08 '25	Sale	135.00	2,223	300,105	6,330	Jul 16 05:55 PM
Izzar Rachid	Officer	Jul 08 '25	Proposed Sale	135.00	2,223	300,105		Jul 08 03:26 PM
Singhal Priya	Head of Development	May 19 '25	Sale	126.25	3,806	480,508	5,427	May 20 04:05 PM
Singhal Priya	Officer	May 19 '25	Proposed Sale	126.25	3,806	480,508		May 19 11:24 AM
Keeney Adam	Head of Corporate Development	May 01 '25	Option Exercise	0.00	938	0	2,838	May 05 04:19 PM
DORSA CAROLINE	Director	May 02 '25	Buy	122.72	1,235	151,559	27,842	May 05 04:17 PM
SHERWIN STEPHEN A	Director	Mar 07 '25	Sale	150.02	8,760	1,314,142	11,318	Mar 10 04:09 PM
STEPHEN A SHERWIN	Director	Mar 07 '25	Proposed Sale	147.37	8,760	1,290,961		Mar 07 04:18 PM
Singhal Priya	Head of Development	Feb 10 '25	Option Exercise	0.00	1,212	0	9,423	Feb 12 05:48 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 10 '25	Option Exercise	0.00	2,272	0	14,725	Feb 12 05:47 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 10 '25	Option Exercise	0.00	3,257	0	25,712	Feb 12 05:46 PM
Kramer Robin	Chief Accounting Officer	Feb 10 '25	Option Exercise	0.00	834	0	8,257	Feb 12 05:44 PM
Gregory Ginger	EVP, Human Resources	Feb 10 '25	Option Exercise	0.00	2,159	0	18,232	Feb 12 05:43 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 10 '25	Option Exercise	0.00	2,575	0	37,072	Feb 12 05:42 PM
Izzar Rachid	Head of Global Product Strat.	Feb 10 '25	Option Exercise	0.00	1,515	0	8,998	Feb 12 05:40 PM
Izzar Rachid	Head of Global Product Strat.	Feb 07 '25	Option Exercise	0.00	3,844	0	7,860	Feb 11 09:52 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 07 '25	Option Exercise	0.00	4,551	0	23,171	Feb 10 06:59 PM
Viehbacher Christopher	President and CEO	Feb 07 '25	Option Exercise	0.00	9,008	0	16,008	Feb 10 06:55 PM
Grogan Jane	Head of Research	Feb 07 '25	Option Exercise	0.00	1,385	0	1,876	Feb 10 06:52 PM
Keeney Adam	Head of Corporate Development	Feb 07 '25	Option Exercise	0.00	1,801	0	2,463	Feb 10 06:51 PM
Kramer Robin	Chief Accounting Officer	Feb 07 '25	Option Exercise	0.00	1,491	0	7,667	Feb 10 06:48 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 07 '25	Option Exercise	0.00	4,042	0	13,056	Feb 10 06:47 PM
Singhal Priya	Head of Development	Feb 07 '25	Option Exercise	0.00	2,216	0	8,892	Feb 10 06:45 PM
Gregory Ginger	EVP, Human Resources	Feb 07 '25	Option Exercise	0.00	3,436	0	16,633	Feb 10 06:44 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 07 '25	Option Exercise	0.00	4,130	0	35,088	Feb 10 06:42 PM

Open in Screener

VSTM

Verastem Inc

Feb 06 • 04:00PM ET

6.67

+0.39 6.21 %

Healthcare • Biotechnology • USA • NASD

Peers: GILD AMGN MRK PFE BMY REGN VRTX INCY LUMO SRPT

| Held by: VTI XBI IWM VXF FESM VTWO IWO IWN VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-4.26	Insider Own	13.77%	Shs Outstand	66.75M	Perf Week	9.34%
Market Cap	502.38M	Forward P/E	-	EPS next Y	-1.70	Insider Trans	-0.72%	Shs Float	64.95M	Perf Month	-12.70%
Enterprise Value	454.15M	PEG	-	EPS next Q	-0.52	Inst Own	80.96%	Short Float	26.35%	Perf Quarter	-18.26%
Income	-241.10M	P/S	37.55	EPS this Y	15.01%	Inst Trans	9.21%	Short Ratio	8.46	Perf Half Y	18.68%
Sales	13.38M	P/B	-	EPS next Y	45.21%	ROA	-159.02%	Short Interest	17.12M	Perf YTD	-13.60%
Book/sh	-0.23	P/C	3.65	EPS next 5Y	40.01%	ROE	-2888.70%	52W High	11.24 -40.68%	Perf Year	12.10%
Cash/sh	1.83	P/FCF	-	EPS past 3/5Y	9.28% 31.36%	ROIC	-350.20%	52W Low	4.01 66.33%	Perf 3Y	-13.73%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	154.59% -10.54%	Gross Margin	80.93%	Volatility	7.29% 7.02%	Perf 5Y	-73.15%
Dividend TTM	-	EV/Sales	33.94	EPS Y/Y TTM	-26.37%	Oper. Margin	-1197.72%	ATR (14)	0.50	Perf 10Y	-53.68%
Dividend Ex-Date	-	Quick Ratio	2.55	Sales Y/Y TTM	33.79%	Profit Margin	-1802.12%	RSI (14)	46.84	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.58	EPS Q/Q	-126.22%	SMA20	1.05%	Beta	0.38	Target Price	16.62
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-15.94%	Rel Volume	0.63	Prev Close	6.28
Employees	78	LT Debt/Eq	-	Earnings	Nov 04 BMO	SMA200	-12.43%	Avg Volume	2.02M	Price	6.67
IPO	Jan 27, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	-118.91% 95.30%	Trades		Volume	1,278,663	Change	6.21%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-04-26	Initiated	H.C. Wainwright	Buy	$18
Oct-16-25	Resumed	Cantor Fitzgerald	Overweight
Apr-10-25	Initiated	Jefferies	Buy	$15
Mar-24-25	Reiterated	H.C. Wainwright	Buy	$7 → $10
Dec-31-24	Reiterated	BTIG Research	Buy	$13 → $20
Sep-30-24	Initiated	Guggenheim	Buy	$13
Nov-21-23	Resumed	BTIG Research	Buy	$27
Sep-27-23	Initiated	B. Riley Securities	Buy	$21
Jun-15-23	Upgrade	Mizuho	Neutral → Buy	$24 → $36
Sep-07-22	Resumed	Alliance Global Partners	Buy	$6
Apr-29-22	Resumed	Cantor Fitzgerald	Overweight	$6 → $5
Apr-14-22	Initiated	RBC Capital Mkts	Outperform	$5
Mar-09-22	Initiated	Truist	Buy	$6
Jul-01-21	Initiated	Alliance Global Partners	Buy	$6
May-24-21	Upgrade	BTIG Research	Neutral → Buy	$8
Jun-20-19	Downgrade	BTIG Research	Buy → Neutral
May-10-19	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-13-18	Initiated	BTIG Research	Buy	$17
May-02-18	Initiated	Seaport Global Securities	Buy	$14
Mar-08-18	Initiated	B. Riley FBR, Inc.	Buy	$15

Show Previous Ratings

Feb-05-26 11:42AM	Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results (Zacks) -7.51%
Feb-04-26 08:00AM	Here Are Wednesdays Top Wall Street Analyst Research Calls: AES Corp, Airbnb, Cloudflare, Devon Energy, Levi Strauss, Lumentum, PayPal, and More (24/7 Wall St.) +7.78%
07:30AM	Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers (Business Wire)
Jan-30-26 10:19AM	$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors (PR Newswire)
Jan-12-26 04:01PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.73%
03:33PM	Loading…
Jan-07-26 03:33PM	Revolution Medicines stock surges over 20% on potential AbbVie acquisition (Investing.com) +11.05%
Dec-29-25 04:01PM	Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (Business Wire)
Dec-15-25 04:01PM	Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth (Business Wire) -6.80%
Nov-25-25 07:30AM	Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference (Business Wire)
Nov-14-25 07:57AM	TEM Continues to Strengthen Its Genomics Leadership With New Products (Zacks) -6.84%
12:41AM	Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Nov-13-25 04:07PM	Verastem Oncology Announces Proposed Public Offering of Common Stock (Business Wire)
Nov-05-25 07:30AM	Verastem Oncology to Present at Upcoming Investor Conferences (Business Wire)
Nov-04-25 04:02PM	Verastem Inc (VSTM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Rising ... (GuruFocus.com) -20.10%
08:40AM	Verastem (VSTM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:40AM	Loading…
07:40AM	Verastem: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates (Business Wire)
Nov-03-25 12:00PM	Verastem (VSTM) Upgraded to Buy: Here's Why (Zacks)
Oct-29-25 11:57AM	Verastem, Inc. (VSTM) Delivers Positive Preliminary Data for VS-7375 in Mutant Solid Tumors Treatment (Insider Monkey)
Oct-28-25 11:35AM	3 Cancer-Focused Stocks Showing Strong Pipeline Progress (Zacks)
Oct-23-25 04:01PM	Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors (Business Wire)
09:55AM	Verastem (VSTM) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
07:30AM	Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025 (Business Wire)
Oct-21-25 10:00AM	Best Momentum Stocks to Buy for Oct. 21 (Zacks)
06:39AM	New Strong Buy Stocks for Oct. 21: NEM, AS and More (Zacks)
Oct-20-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Verastem (VSTM) is a Great Choice (Zacks) -13.02%
09:55AM	Wall Street Analysts Think Verastem (VSTM) Could Surge 68.11%: Read This Before Placing a Bet (Zacks)
Oct-19-25 04:15AM	Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma (Business Wire)
Oct-07-25 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-19-25 12:00PM	Verastem (VSTM) Upgraded to Buy: Here's What You Should Know (Zacks) -5.14%
01:13PM	Loading…
Sep-16-25 01:13PM	Top Biotech Picks for 2025: BTIG Research Highlights Potential Winners (Investing.com) -7.03%
Aug-27-25 07:00AM	Verastem Oncology to Present at Upcoming Investor Conferences (Business Wire)
Aug-17-25 03:22AM	Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects (Insider Monkey)
Aug-13-25 04:29PM	Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer (Business Wire)
Aug-07-25 06:40PM	Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +19.93%
05:36PM	Verastem: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates (Business Wire)
Aug-05-25 05:55PM	Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-31-25 10:00AM	Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline (Zacks)
Jul-29-25 07:30AM	Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 (Business Wire)
Jul-24-25 07:30AM	Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer (Business Wire)
Jul-23-25 09:26AM	High-Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds (PR Newswire)
Jul-14-25 07:42AM	Verastems avutometinib combination shows 31% ORR in ovarian cancer trial (Clinical Trials Arena) +5.87%
Jul-11-25 04:12PM	Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology (Business Wire)
Jul-08-25 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-30-25 04:02PM	Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer (Business Wire)
Jun-24-25 04:02PM	Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors (Business Wire) -5.70%
Jun-20-25 08:41AM	Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building? (Zacks) -5.01%
Jun-02-25 09:40AM	Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor (Business Wire) -19.95%
May-28-25 10:43AM	VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval (Zacks) -10.68%
07:30AM	Verastem Oncology to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-23-25 05:15PM	Verastem announces positive Phase 1/2 safety and efficacy results in PDAC (TipRanks) +11.10%
May-22-25 05:01PM	Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma (Business Wire)
May-20-25 11:39AM	Tempus partners with Verastem for companion diagnostic development (Medical Device Network)
08:30AM	Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment (Business Wire)
May-13-25 04:50PM	Verastem: Q1 Earnings Snapshot (Associated Press Finance)
04:34PM	Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates (Business Wire)
May-09-25 11:55AM	FDA grants accelerated approval to avutometinib, defactinib combination (TipRanks)
May-08-25 02:47PM	FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer (Benzinga)
01:17PM	FDA Approves the AVMAPKI FAKZYNJA Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
May-01-25 07:30AM	Verastem Oncology to Present at Upcoming Investor Conferences (Business Wire)
Apr-25-25 09:00AM	Verastem Oncology Announces $75 million Private Placement (Business Wire)
Apr-23-25 04:05PM	Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors (Business Wire) +5.34%
Apr-22-25 10:39AM	Verastem Oncology to Report Q1 Earnings: What's in the Cards? (Zacks) +13.37%
Apr-16-25 09:45AM	Top Cancer Stocks to Buy to Boost Your Portfolio's Health (Zacks)
Apr-10-25 02:35PM	Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination (Seeking Alpha) -14.39%
Apr-07-25 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-27-25 09:55AM	Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade (Zacks) +5.16%
Mar-25-25 04:35PM	Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025 (Business Wire)
Mar-20-25 05:15PM	Verastem files to sell 1.42M shares of common stock by selling shareholders (SeekingAlpha)
04:17PM	Verastem: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates (Business Wire)
Mar-08-25 07:33AM	Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge (PR Newswire)
Feb-20-25 04:05PM	Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Womens Cancer (Business Wire)
Jan-29-25 07:30AM	Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference (Business Wire)
Jan-23-25 07:30AM	Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers (Business Wire)
Jan-15-25 07:30AM	Verastem Oncology Names Matthew E. Ros as Chief Operating Officer (Business Wire) +5.36%
Jan-14-25 07:30AM	Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China (Business Wire) -5.62%
Jan-13-25 07:30AM	Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025 (Business Wire) -6.81%
Jan-08-25 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.79%
Dec-31-24 10:33AM	Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Therapy Application (GuruFocus.com) +40.87%
Dec-30-24 04:30PM	Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer (Business Wire)
Dec-20-24 07:00AM	Applied Therapeutics Appoints John H. Johnson as Executive Chairman (GlobeNewswire) -5.63%
Dec-18-24 07:30AM	Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (Business Wire) -7.39%
Nov-26-24 07:00AM	Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-06-24 05:00PM	Verastem: Q3 Earnings Snapshot (Associated Press Finance) -6.98%
04:05PM	Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates (Business Wire)
Nov-01-24 12:02PM	Verastem Oncology submits NDA for ovarian cancer treatment (Pharmaceutical Technology)
Oct-31-24 04:01PM	Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer (Business Wire)
07:30AM	Verastem Oncology to Participate in Upcoming Investor Conferences (Business Wire)
Oct-17-24 01:00AM	Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting (Business Wire) -20.12%
Oct-09-24 06:00AM	Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting (Business Wire)
Oct-07-24 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-10-24 04:05PM	Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference (Business Wire) +8.76%
07:30AM	Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting (Business Wire)
Sep-03-24 07:30AM	Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024 (Business Wire)
Aug-08-24 06:18PM	Verastem: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates (Business Wire)
Jul-29-24 04:01PM	Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer (Business Wire) -7.43%
Jul-23-24 11:20PM	Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants (Business Wire) -17.55%

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Paterson Dan	President and CEO	Feb 04 '26	Sale	6.69	970	6,489	612,919	Feb 05 04:10 PM
Dan Paterson	Officer	Jan 12 '26	Proposed Sale	7.16	5,039	36,069		Jan 14 05:15 PM
Dan Paterson	Officer, Director	Jan 12 '26	Proposed Sale	7.16	10,321	73,851		Jan 14 05:13 PM
Paterson Dan	President and CEO	Jan 12 '26	Sale	7.16	10,321	73,898	400,104	Jan 14 05:12 PM
Calkins Daniel	Chief Financial Officer	Jan 12 '26	Sale	7.16	5,039	36,079	104,719	Jan 14 05:11 PM
Calkins Daniel	Chief Financial Officer	Dec 24 '25	Sale	7.86	80	629	109,758	Dec 29 12:24 PM
Stuglik Brian M	Director	Dec 16 '25	Sale	9.14	592	5,411	101,147	Dec 18 04:47 PM
Paterson Dan	President and CEO	Dec 16 '25	Sale	9.14	393	3,592	410,425	Dec 18 04:46 PM
Gagnon Robert E.	Director	Dec 16 '25	Sale	9.14	283	2,587	41,678	Dec 18 04:45 PM
Paterson Dan	President and CEO	Dec 10 '25	Sale	10.07	2,000	20,140	412,818	Dec 12 05:06 PM
Paterson Dan	President and CEO	Dec 11 '25	Sale	10.00	2,000	20,000	410,818	Dec 12 05:06 PM
Paterson Dan	President and CEO	Dec 05 '25	Sale	10.61	2,000	21,220	418,818	Dec 09 05:03 PM
Paterson Dan	President and CEO	Dec 08 '25	Sale	10.50	2,000	21,000	416,818	Dec 09 05:03 PM
Paterson Dan	President and CEO	Dec 09 '25	Sale	10.25	2,000	20,500	414,818	Dec 09 05:03 PM
Paterson Dan	Officer	Dec 09 '25	Proposed Sale	10.27	7,790	80,003		Dec 09 03:11 PM
Paterson Dan	President and CEO	Dec 02 '25	Sale	10.32	2,000	20,640	424,818	Dec 04 04:54 PM
Paterson Dan	President and CEO	Dec 04 '25	Sale	10.00	2,000	20,000	420,818	Dec 04 04:54 PM
Paterson Dan	President and CEO	Dec 03 '25	Sale	10.00	2,000	20,000	422,818	Dec 04 04:54 PM
Paterson Dan	President and CEO	Nov 28 '25	Sale	10.79	2,000	21,580	428,818	Dec 01 04:40 PM
Paterson Dan	President and CEO	Dec 01 '25	Sale	10.39	2,000	20,780	426,818	Dec 01 04:40 PM
Paterson Dan	President and CEO	Nov 26 '25	Sale	10.32	2,000	20,640	430,818	Dec 01 04:40 PM
Bunn Paul A.	Director	Nov 21 '25	Option Exercise	3.27	6,250	20,438	8,333	Nov 25 05:35 PM
Bunn Paul A.	Director	Nov 21 '25	Sale	10.00	6,250	62,500	2,083	Nov 25 05:35 PM
Kauffman Michael	Director	Nov 21 '25	Sale	10.00	8,550	85,500	8,666	Nov 25 05:34 PM
Paterson Dan	President and CEO	Nov 25 '25	Sale	10.00	2,000	20,000	432,818	Nov 25 05:32 PM
Paterson Dan	President and CEO	Nov 24 '25	Sale	10.00	2,000	20,000	434,818	Nov 25 05:32 PM
Paterson Dan	President and CEO	Nov 21 '25	Sale	10.00	2,000	20,000	436,818	Nov 25 05:32 PM
Kauffman Michael	Board Member	Nov 21 '25	Proposed Sale	9.81	8,550	83,876		Nov 21 04:20 PM
Bunn Paul A.	Board Member	Nov 21 '25	Proposed Sale	9.81	6,250	61,312		Nov 21 04:10 PM
Paterson Dan	President and CEO	Nov 03 '25	Sale	9.74	3,299	32,146	438,818	Nov 06 12:21 PM
Bunn Paul A.	Director	Oct 09 '25	Sale	9.06	8,333	75,497	8,333	Oct 14 04:31 PM
Bunn Paul A.	Board Member	Oct 09 '25	Proposed Sale	8.94	8,333	74,497		Oct 09 04:05 PM
Calkins Daniel	Chief Financial Officer	Sep 22 '25	Sale	9.08	57	518	109,863	Sep 24 04:30 PM
Calkins Daniel	Chief Financial Officer	Sep 24 '25	Sale	9.23	25	231	109,838	Sep 24 04:30 PM
Stuglik Brian M	Director	Sep 16 '25	Sale	9.99	587	5,864	101,739	Sep 18 06:16 PM
Gagnon Robert E.	Director	Sep 16 '25	Sale	9.99	281	2,807	41,961	Sep 18 06:14 PM
Paterson Dan	President and CEO	Sep 16 '25	Sale	9.99	390	3,896	442,117	Sep 18 06:11 PM
Paterson Dan	Officer	Sep 17 '25	Proposed Sale	9.76	31,790	310,429		Sep 04 12:39 PM
Paterson Dan	President and CEO	Aug 06 '25	Sale	5.81	1,332	7,739	442,507	Aug 06 08:38 PM
Paterson Dan	President and CEO	Jun 20 '25	Sale	5.13	17,808	91,355	443,839	Jun 24 04:39 PM
Calkins Daniel	Chief Financial Officer	Jun 20 '25	Sale	5.13	4,110	21,084	109,945	Jun 24 04:37 PM
Calkins Daniel	Chief Financial Officer	Jun 23 '25	Sale	4.71	25	118	109,920	Jun 24 04:37 PM
Dan Paterson	Officer	Jun 20 '25	Proposed Sale	5.13	17,808	91,334		Jun 20 05:35 PM
Paterson Dan	President and CEO	Jun 16 '25	Sale	5.65	335	1,893	461,647	Jun 20 11:22 AM
Gagnon Robert E.	Director	Jun 16 '25	Sale	5.65	284	1,605	42,242	Jun 20 11:22 AM
Stuglik Brian M	Director	Jun 16 '25	Sale	5.65	594	3,356	102,326	Jun 20 11:21 AM
Calkins Daniel	Chief Financial Officer	May 20 '25	Sale	8.13	11,143	90,593	114,055	May 20 07:54 PM
Paterson Dan	President and CEO	May 20 '25	Sale	8.13	58,677	477,044	461,982	May 20 07:52 PM
Daniel Calkins	Officer	May 20 '25	Proposed Sale	8.10	11,143	90,293		May 20 07:49 PM
Dan Paterson	Officer, Director	May 20 '25	Proposed Sale	8.13	58,677	477,044		May 20 07:48 PM
Paterson Dan	President and CEO	May 05 '25	Sale	7.30	820	5,986	345,659	May 07 04:30 PM
Calkins Daniel	Chief Financial Officer	Mar 20 '25	Sale	6.89	65	448	86,374	Mar 24 04:39 PM
Calkins Daniel	Chief Financial Officer	Mar 24 '25	Sale	7.04	26	183	86,348	Mar 24 04:39 PM
Paterson Dan	President and CEO	Mar 17 '25	Sale	6.95	244	1,696	346,479	Mar 19 04:48 PM
Gagnon Robert E.	Director	Mar 17 '25	Sale	6.95	284	1,974	34,193	Mar 19 04:47 PM
Stuglik Brian M	Director	Mar 17 '25	Sale	6.95	593	4,121	94,587	Mar 19 04:46 PM

BIIB

Biogen Inc

VSTM

Verastem Inc

Upgrade your FINVIZ experience